The Intervention Clinical Trials Program has three primary research objectives:
Develop new medications to treat unresponsive symptoms
We research new medications and treatments to treat psychosis (hallucinations, delusions and disorganization), cognition (memory and attention) and negative symptoms (apathy, social withdrawal and loss of emotional expressiveness). The development of new treatments is guided by new findings in genetics and neuroimaging.
Improve existing medications
We seek to improve existing options through such strategies as combining medication, optimizing dosing and improving compliance.
Mitigate side effects and medical complications associated with these medications
We have made groundbreaking progress in understanding the mechanisms by which certain antipsychotics cause weight gain and may increase the risk for diabetes. We are looking at experimental alternatives that could prevent these side effects.
We also investigate how certain medications elevate prolactin and the long-term health consequences.